Dicerna Pharmaceuticals Inc. (DRNA) Sees Large Volume Increase
Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) saw strong trading volume on Friday . 226,453 shares traded hands during trading, an increase of 38% from the previous session’s volume of 163,539 shares.The stock last traded at $3.34 and had previously closed at $3.31.
A number of equities research analysts have issued reports on the company. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. Chardan Capital cut their price target on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research note on Monday. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research note on Thursday, May 12th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. Finally, Jefferies Group reiterated a “buy” rating and set a $19.00 price objective on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $11.85.
The stock’s 50-day moving average price is $3.27 and its 200 day moving average price is $4.45. The company’s market capitalization is $71.50 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.09. Analysts predict that Dicerna Pharmaceuticals Inc. will post ($3.21) earnings per share for the current year.
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.